ABT-199
cell death
hairy cell leukemia
leukemia microenvironment
venetoclax
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
08
2020
accepted:
18
06
2021
entrez:
12
8
2021
pubmed:
13
8
2021
medline:
13
8
2021
Statut:
epublish
Résumé
Current standard treatment of patients with hairy cell leukemia (HCL), a chronic B-cell neoplasia of low incidence that affects the elderly, is based on the administration of purine analogs such as cladribine. This chemotherapy approach shows satisfactory responses, but the disease relapses, often repeatedly. Venetoclax (ABT-199) is a Bcl-2 inhibitor currently approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in adult patients ineligible for intensive chemotherapy. Given that HCL cells express Bcl-2, our aim was to evaluate venetoclax as a potential therapy for HCL. We found that clinically relevant concentrations of venetoclax (0.1 and 1 µM) induced primary HCL cell apoptosis
Identifiants
pubmed: 34381700
doi: 10.3389/fonc.2021.598319
pmc: PMC8350736
doi:
Types de publication
Journal Article
Langues
eng
Pagination
598319Informations de copyright
Copyright © 2021 Vereertbrugghen, Colado, Gargiulo, Bezares, Fernández Grecco, Cordini, Custidiano, François, Berchem, Borge, Paggetti, Moussay, Gamberale, Giordano and Morande.
Déclaration de conflit d'intérêts
RB receives payment from Microsules and Varifarma. GC receives payment for lectures from Janssen. RC receives payment for lectures from AtraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Target Oncol. 2020 Apr;15(2):147-162
pubmed: 32319019
Leuk Lymphoma. 1998 Feb;28(5-6):567-72
pubmed: 9613987
Blood Cancer J. 2014 Feb 14;4:e184
pubmed: 24531447
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Clin Adv Hematol Oncol. 2018 Mar;16(3):205-215
pubmed: 29742076
Haematologica. 2018 Oct;103(10):e458-e461
pubmed: 29748439
Front Oncol. 2019 Jan 07;8:645
pubmed: 30666297
Br J Haematol. 2014 Jul;166(2):177-88
pubmed: 24697238
Leuk Lymphoma. 2019 Dec;60(12):2869-2879
pubmed: 31068044
Semin Cancer Biol. 2014 Feb;24:71-81
pubmed: 24018164
Mol Cell. 2020 Jun 18;78(6):1045-1054
pubmed: 32516599
Leukemia. 2013 Jan;27(1):241-5
pubmed: 22705994
Blood. 2016 Aug 18;128(7):934-47
pubmed: 27297795
Leukemia. 2020 Feb;34(2):478-487
pubmed: 31471562
Am J Hematol. 2019 Dec;94(12):1413-1422
pubmed: 31591741
Semin Cancer Biol. 2014 Feb;24:43-8
pubmed: 23831274
Blood. 2012 May 31;119(22):5332-3
pubmed: 22653958
Blood. 1999 Jan 1;93(1):251-9
pubmed: 9864168
Blood. 1994 Nov 1;84(9):3134-41
pubmed: 7524766
Leukemia. 2014 Jun;28(6):1207-15
pubmed: 24402163
Curr Hematol Malig Rep. 2019 Oct;14(5):469-476
pubmed: 31512151
Cell Death Dis. 2015 Jan 15;6:e1593
pubmed: 25590803
Leuk Lymphoma. 2011 Jun;52 Suppl 2:94-8
pubmed: 21438839
Intern Med. 2015;54(10):1287-9
pubmed: 25986272
Blood. 2015 Feb 19;125(8):1207-16
pubmed: 25480661
Leuk Res. 2007 Sep;31(9):1231-6
pubmed: 17462732
Am J Hematol. 2018 Dec;93(12):1568-1569
pubmed: 30152528
Cells. 2020 May 21;9(5):
pubmed: 32455818
Best Pract Res Clin Haematol. 2015 Dec;28(4):208-16
pubmed: 26614899
Expert Rev Hematol. 2019 Nov;12(11):983-987
pubmed: 31380711